NEPH NEPHROS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1196298 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.4%
TTM net income YoY29.0%
TTM EPS YoY28.6%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR—
Margins
Gross margin60.5%
Operating margin8.5%
Net margin8.9%
FCF margin—
EBITDA margin9.0%
Returns
ROE16.9%
ROA13.4%
ROIC (approx.)22.5%
Asset turnover1.51x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio19.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.62M | $6.02M | $5.21M | $4.73M | $4.76M | $4.42M | $4.88M | $3.87M |
| Cost of revenue | $2.34M | $1.99M | $2.22M | $1.97M | $1.85M | $1.62M | $1.72M | $1.40M |
| Gross profit | $3.29M | $4.03M | $2.99M | $2.76M | $2.92M | $2.79M | $3.15M | $2.48M |
| R&D expense | $331,000 | $366,000 | $346,000 | $395,000 | $338,000 | $311,000 | $295,000 | $252,000 |
| SG&A expense | $2.42M | $2.42M | $2.52M | $2.32M | $2.23M | $2.20M | $2.25M | $1.87M |
| Operating income | $501,000 | $1.21M | $97,000 | $18,000 | $314,000 | $248,000 | $566,000 | $317,000 |
| Interest expense | $0 | $1,000 | — | $0 | $0 | $1,000 | — | $0 |
| Pretax income | $512,000 | $1.21M | — | $62,000 | $340,000 | $246,000 | — | $364,000 |
| Income tax | $0 | $13,000 | $0 | $0 | $3,000 | $9,000 | $0 | $15,000 |
| Net income | $512,000 | $1.20M | $140,000 | $62,000 | $337,000 | $237,000 | $558,000 | $349,000 |
| EBITDA | $530,000 | $1.24M | $126,000 | $50,000 | $348,000 | $283,000 | $605,000 | $351,000 |
| EPS (basic) | 0.05 | 0.11 | 0.01 | — | 0.03 | 0.02 | 0.05 | — |
| EPS (diluted) | 0.05 | 0.11 | 0.01 | — | 0.03 | 0.02 | 0.05 | — |
| Weighted avg. shares (diluted) | 11.20M | 11.11M | 10.99M | — | 11.04M | 10.81M | 10.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.55M | $4.70M | $4.02M | $5.40M | $5.17M | $5.07M | $4.08M | $3.76M |
| Receivables | $3.58M | $4.10M | $3.52M | $2.41M | $2.66M | $2.04M | $2.68M | $1.78M |
| Inventory | $4.95M | $4.55M | $3.62M | $3.23M | $2.74M | $2.24M | $1.95M | $2.62M |
| Current assets | $13.26M | $13.60M | $11.50M | $11.22M | $10.71M | $9.58M | $8.99M | $8.30M |
| PP&E, net | $72,000 | $83,000 | $95,000 | $106,000 | $119,000 | $131,000 | $143,000 | $161,000 |
| Goodwill | $759,000 | $759,000 | $759,000 | $759,000 | $759,000 | $759,000 | $759,000 | $759,000 |
| Intangibles | $294,000 | $302,000 | $310,000 | $318,000 | $326,000 | $334,000 | $341,000 | $349,000 |
| Total assets | $15.30M | $15.77M | $13.79M | $13.64M | $13.25M | $12.24M | $11.78M | $11.21M |
| Current liabilities | $2.41M | $3.34M | $2.53M | $2.77M | $2.47M | $1.77M | $1.52M | $1.56M |
| Total liabilities | $2.76M | $3.80M | $3.09M | $3.44M | $3.24M | $2.64M | $2.49M | $2.62M |
| Shareholders' equity | $12.55M | $11.97M | $10.70M | $10.20M | $10.01M | $9.60M | $9.29M | $8.59M |
| Shares outstanding | 10.87M | 10.86M | 10.84M | 10.64M | 10.63M | 10.60M | 10.60M | 10.54M |
| Cash flow statement | ||||||||
| Operating cash flow | -$150,000 | $681,000 | -$1.67M | $230,000 | $99,000 | $994,000 | $322,000 | $1.30M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | $1.30M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | -$1,000 | -$2,000 | $289,000 | -$1,000 | -$2,000 | -$1,000 | -$1,000 | -$1,000 |
| Depreciation & amortization | $29,000 | $29,000 | $29,000 | $32,000 | $34,000 | $35,000 | $39,000 | $34,000 |
| Stock-based compensation | $60,000 | $61,000 | $60,000 | $79,000 | $70,000 | $71,000 | $76,000 | $62,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.